Morgan Stanley analyst Sean Laaman raised the firm’s price target on BridgeBio (BBIO) to $98 from $96 and keeps an Overweight rating on the shares. The firm updated estimates following the company’s Q4 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio price target raised to $125 from $100 at Evercore ISI
- BridgeBio price target lowered to $81 from $83 at Oppenheimer
- BridgeBio Pharma: Clear Path to 2027 Profitability with Underappreciated Pipeline Upside
- BridgeBio: Robust Attruby Launch and Late-Stage Pipeline Support Buy Rating and Path to Sustainable Cash Generation
- BridgeBio reports Q4 EPS ($1.00), consensus (67c)